Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.

H Brümmendorf, Tim; E Cortes, Jorge; Milojkovic, Dragana; Gambacorti-Passerini, Carlo; E Clark, Richard; le Coutre, Philipp; Garcia-Gutierrez, Valentin; Chuah, Charles; Kota, Vamsi; H Lipton, Jeffrey; Rousselot, Philippe; J Mauro, Michael; Hochhaus, Andreas; Hurtado Monroy, Rafael; Leip, Eric; Purcell, Simon; Yver, Anne; Viqueira, Andrea; W Deininger, Michael; study investigators, BFORE

doi:10.1038/s41375-022-01589-y

Public

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.

Shared by NobleBlocks on Jul 1, 2022 • 12:00 AM UTC

Authors:

Tim H Brümmendorf

Jorge E Cortes

Dragana Milojkovic

Abstract

This analysis from the multicenter, open-label, phase 3 BFORE trial reports efficacy and safety of bosutinib in patients with newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML) after five years' follow-up. Patients were randomized to 400-mg once-daily bosutinib (n = 268) or imatinib (...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!